SCHEMBL1993836

SCHEMBL1993836

Cn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(N3CCc4ccc(F)cc4C3)nc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 5/20 0.38
ALDH1A1 P00352 5/20 0.38
GSR P00390 1/20 0.38
SYK P43405 2/20 0.37
TSHR P16473 3/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPK14 Q16539 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2000181 0.94 ALDH1A1 (0.38) TRPV4ALDH1A1GSRSYKTSHR
SCHEMBL1996514 0.94 TRPV4 (0.40) TRPV4ALDH1A1SYKTSHRMAPT
SCHEMBL1992226 0.93 ALDH1A1 (0.40) TRPV4ALDH1A1SYKTSHRMAPT
SCHEMBL1990420 0.81 PDE10A (0.36) TRPV4ALDH1A1TSHRCYP1A2CYP3A4
SCHEMBL5442053 0.80 TRPV4 (0.46) TRPV4ALDH1A1TSHRMAPTCYP1A2
SCHEMBL1989787 0.80 KCNH2 (0.38) TRPV4ALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL1996822 0.79 ALDH1A1 (0.54) TRPV4ALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL1991408 0.79 TRPV4 (0.34) TRPV4ALDH1A1TSHRCYP1A2CYP3A4
SCHEMBL1990180 0.78 ALDH1A1 (0.53) ALDH1A1TSHRMAPTSMN1; SMN2CYP1A2
SCHEMBL1990566 0.76 ALDH1A1 (0.44) ALDH1A1SYKTSHRSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866310-B1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME (GB) 2012-07-11 EP disclosed
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists MERCK SHARP & DOHME LTD. (GB) 2011-06-23 US disclosed
EP-1866310-A1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-12-19 EP disclosed
WO-2006100520-A1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists NR2C2, NR3C2, NR2E3 TRPV4 1580/4885ALDH1A1 1796/4885GSR 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.